Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Francesco Giunta

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
The Journal of Pathology|July 8, 2026
Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, et al.
Current Treatment Options in Oncology|April 17, 2021
Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine TherapyAnna Diana, Francesca Carlino, Emilio Francesco Giunta, et al.
British Journal of Cancer|April 23, 2020
Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patientsTeresa Troiani, Emilio Francesco Giunta, Martina Tufano, et al.
JAMA Network Open|April 16, 2024
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-AnalysisGiuseppe Luigi Banna, Mona Ali Hassan, Alessio Signori, et al.
The Oncologist|August 12, 2025
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia related to PARP inhibitor Maintenance Line in Real-world Ovarian Cancer PatientsAlberto Farolfi, Chiara Casadei, Nicola Gentili, et al.
Cancers|November 13, 2021
Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current EvidenceSara Elena Rebuzzi, Giuseppe Luigi Banna, Veronica Murianni, et al.
Expert Review of Anticancer Therapy|December 24, 2024
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancerRiccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, et al.
International Journal of Molecular Sciences|August 12, 2023
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate CancerMaria Concetta Cursano, Emilio Francesco Giunta, Emanuela Scarpi, et al.
Therapeutic Advances in Medical Oncology|January 27, 2025
Rare epithelial gastric cancers: a review of the current treatment knowledgeAngelica Petrillo, Margaret Ottaviano, Luca Pompella, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2022
Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trialsGiuseppe Luigi Banna, Alessio Signori, Alessandra Curioni-Fontecedro, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
The Journal of Pathology|July 8, 2026
Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, et al.
Current Treatment Options in Oncology|April 17, 2021
Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine TherapyAnna Diana, Francesca Carlino, Emilio Francesco Giunta, et al.
British Journal of Cancer|April 23, 2020
Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patientsTeresa Troiani, Emilio Francesco Giunta, Martina Tufano, et al.
JAMA Network Open|April 16, 2024
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-AnalysisGiuseppe Luigi Banna, Mona Ali Hassan, Alessio Signori, et al.
The Oncologist|August 12, 2025
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia related to PARP inhibitor Maintenance Line in Real-world Ovarian Cancer PatientsAlberto Farolfi, Chiara Casadei, Nicola Gentili, et al.
Cancers|November 13, 2021
Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current EvidenceSara Elena Rebuzzi, Giuseppe Luigi Banna, Veronica Murianni, et al.
Expert Review of Anticancer Therapy|December 24, 2024
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancerRiccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, et al.
International Journal of Molecular Sciences|August 12, 2023
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate CancerMaria Concetta Cursano, Emilio Francesco Giunta, Emanuela Scarpi, et al.
Therapeutic Advances in Medical Oncology|January 27, 2025
Rare epithelial gastric cancers: a review of the current treatment knowledgeAngelica Petrillo, Margaret Ottaviano, Luca Pompella, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2022
Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trialsGiuseppe Luigi Banna, Alessio Signori, Alessandra Curioni-Fontecedro, et al.
Pageof 6